Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. (2022)
Attributed to:
'REBRACOVID' - multicentre cohort study of the natural history and immunology of COVID-19 in Brazil
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.17863/cam.82533
Publication URI: https://www.repository.cam.ac.uk/handle/1810/335091
Type: Other